Deerfield Management Company L.P. Series C Makes New $265,000 Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Deerfield Management Company L.P. Series C purchased a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 6,623 shares of the company’s stock, valued at approximately $265,000.

Other hedge funds have also modified their holdings of the company. TD Asset Management Inc grew its stake in Amphastar Pharmaceuticals by 67.4% in the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after purchasing an additional 680,976 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 348.7% during the 4th quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock valued at $36,648,000 after buying an additional 460,473 shares during the last quarter. Boone Capital Management LLC bought a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter valued at approximately $24,740,000. Marshall Wace LLP acquired a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter worth $9,085,000. Finally, American Century Companies Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after purchasing an additional 121,764 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $48.02 on Friday. The firm has a market capitalization of $2.35 billion, a PE ratio of 16.62, a PEG ratio of 0.92 and a beta of 0.82. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The firm’s fifty day simple moving average is $45.39 and its 200 day simple moving average is $42.73.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The business had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. On average, sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current year.

Insider Transactions at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 10,282 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total value of $454,772.86. Following the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,162,175.69. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO William J. Peters sold 10,282 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,162,175.69. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now owns 75,409 shares in the company, valued at $3,504,256.23. The disclosure for this sale can be found here. Insiders sold a total of 34,383 shares of company stock worth $1,524,123 over the last three months. 27.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on AMPH. StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, September 20th. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.